Table 3.
Univariable and multivariable analyses of determinants of full HPV vaccination adherence with those non-adhering to the full vaccination regime as reference group
| Univariable analysis |
Multivariable analysis (n = 3,458) |
|||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p | aOR | 95% CI | p | |
| Age (n = 3,762) | 0.96 | 0.89–1.02 | .193 | 0.99 | 0.91–1.08 | .850 |
| Country of origin (study participant) (n = 3,760) | .001* | .031* | ||||
| Norway | 1 | 1 | ||||
| Not Norway | 0.39 | 0.21–0.65 | 0.43 | 0.47–0.97 | ||
| Country of origin (caregivers) (n = 3,475) | .001* | .468 | ||||
| Both caregivers from Norway | 1 | 1 | ||||
| At least one caregiver from outside of Norway | 0.72 | 0.44–1.16 | 0.75 | 0.45–1.25 | ||
| Both caregivers from outside of Norway | 0.53 | 0.38–0.75 | 0.81 | 0.45–1.45 | ||
| Region of residence (n = 3,762) | .051 | .153 | ||||
| Akershus og Oslo | 1 | 1 | ||||
| Hedmark og Oppland | 1.97 | 1.04–3.72 | 1.87 | 0.93–3.77 | ||
| Østlandet ellers | 1.57 | 1.05–2.34 | 1.69 | 1.08–2.64 | ||
| Agder og Rogaland | 1.20 | 0.83–1.73 | 1.22 | 0.80–1.84 | ||
| Vestlandet | 1.49 | 1.04–2.13 | 1.39 | 0.93–2.07 | ||
| Trøndelag | 1.70 | 1.09–2.64 | 1.66 | 1.02–2.70 | ||
| Nord-Norge | 1.28 | 0.81–2.00 | 1.21 | 0.73–2.00 | ||
| Marital status (n = 3,762) | .009* | .417 | ||||
| Single | 1 | 1 | ||||
| In a relationship | 0.74 | 0.31–0.74 | 0.80 | 0.54–1.17 | ||
| Cohabitating | 0.66 | 0.05–3.23 | 0.71 | 0.51–1.01 | ||
| Married | 0.48 | 0.52–1.05 | 0.76 | 0.46–1.28 | ||
| Separated | 0.38 | 0.49–0.89 | 1.31 | 0.12–13.99 | ||
| Children (n = 3,762) | <.001* | <.001* | ||||
| Yes | 0.54 | 0.41–0.72 | 0.51 | 0.35–0.73 | ||
| Highest completed education (n = 3,762) | .002* | .094 | ||||
| Primary or none | 1 | 1 | ||||
| Secondary | 1.39 | 0.94–2.07 | 1.11 | 0.70–1.77 | ||
| University or college | 1.84 | 1.28–2.64 | 1.46 | 0.94–2.27 | ||
| Household income after tax (in NOK) (n = 3,711) | .689 | |||||
| P10 214000 | 1 | |||||
| P20 266000 | 0.92 | 0.60–1.40 | ||||
| P30 305000 | 0.92 | 0.57–1.47 | ||||
| P40 339000 | 0.96 | 0.59–1.57 | ||||
| P50 372000 | 1.12 | 0.67–1.89 | ||||
| P60 408000 | 1.19 | 0.71–2.01 | ||||
| P70 450000 | 1.31 | 0.77–2.23 | ||||
| P80 507000 | 0.86 | 0.54–1.38 | ||||
| P90 606000 | 0.95 | 0.59–1.54 | ||||
| P100 > 606001 | 0.63 | 0.38–1.04 | ||||
| Ease to find out where you could get the free HPV vaccine (n = 3,762) | 2.05 | 1.82–2.30 | <.001* | 1.94 | 1.69–2.23 | <.001* |
| Receipt of vaccination at your preferred location (n = 3,762) | .002* | .664 | ||||
| Yes | 1.52 | 1.17–1.98 | 1.07 | 0.79–1.45 | ||
| If you wanted to get more information about the vaccines, where would you get this? (multiple locations possible) (n = 3,762) | ||||||
| Internet | 1.16 | 0.85–1.57 | .352 | |||
| Friends or colleagues | 1.04 | 0.79–1.38 | .761 | |||
| Family | 1.24 | 0.90–1.71 | .192 | 1.08 | 0.76–1.54 | .667 |
| Community health service | 1.06 | 0.83–1.35 | .664 | |||
| GP | 1.05 | 0.83–1.33 | .694 | |||
| Health authorities | 1.52 | 1.19–1.95 | .001* | 1.37 | 1.04–1.81 | .025* |
| What were the reasons why you completed the HPV vaccination? (multiple answers possible) | ||||||
| … information from the media (n = 3,754) | 1.18 | 0.92–1.52 | .192 | 1.03 | 0.76–1.41 | .842 |
| … information from NIPH via SMS and social media (n = 3,755) | ||||||
| Country of origin: Norway | 1.09 | 0.81–1.46 | .584 | 0.68 | 0.46–1.01 | .034* |
| Country of origin: Not Norway | 1.76 ▪ | 0.91–3.41 | .092 | 1.48 ▪▪ | 0.69–3.14 | .312 |
| … HPV vaccination was free of charge (n = 3,758) | 0.99 | 0.63–1.54 | .958 | |||
| … HPV vaccination was readily available (n = 3,760) | 3.61 | 2.65–4.90 | <.001* | 2.28 | 1.50–3.37 | <.001* |
| … my parents and/or friends thought I should take the vaccination (n = 3,762) | 1.37 | 1.06–1.76 | .017* | 1.20 | 0.89–1.62 | .226 |
| … healthcare professionals and central health authorities recommended vaccination (n = 3,761) | 1.34 | 0.98–1.85 | .070 | 0.68 | 0.46–1.01 | .057 |
| … the vaccine can prevent cervical cancer (n = 3,761) | 2.16 | 1.30–3.57 | .003* | 1.31 | 0.70–2.43 | .395 |
| … I, or someone I know, has had cell changes/cervical cancer (n = 3,756) | 0.99 | 0.78–1.25 | .904 | |||
▪The estimate of OR of receiving information from FHI via SMS and social media for study participants whose country of origin is not Norway is based on the multiplication of the estimate of the OR of study participants whose country of origin was Norway (presented in the Table 3) * the interaction term (1.62 (95%CI: 0.79–3.35), p-value: 0.19).
▪▪The estimate of aOR of receiving information from FHI via SMS and social media for study participants whose country of origin is not Norway is based on the multiplication of the estimate of the aOR of study participants whose country of origin was Norway (presented in the Table 3) * the interaction term (2.18 (95%CI: 0.98–4.88), p-value: 0.06).
* = p value significant at p < .05.
(a)OR = (adjusted)odds ratio.